Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Erlotinib in EGFR-mutant Lung Adenocarcinoma
NCT02155465Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in lung adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximally Tolerated Dose at 1 year and Overall Response Rate at 1 year. Started Jun 2014; status: completed.
02
Drugs
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02155465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02155465.